Results 301 to 310 of about 94,528 (347)

Supplemental Figure 8 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Apostolia M. Tsimberidou, Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Anna Nowak, Katrin Aslan, Arun Satelli, Fabian Richter, Sabrina Kuttruff-Coqui, Oliver Schoor, Jens Fritsche, Zoe Coughlin, Ali S. Mohamed, Kerry Sieger, Becky Norris, Rita Ort, Jennifer Beck, Henry Hiep Vo, Franziska Hoffgaard, Manuel Ruh, Linus Backert, Ignacio I. Wistuba, David Fuhrmann, Nuhad K. Ibrahim, Van K. Morris, Bryan K. Kee, Daniel M. Halperin, Graciela M. Nogueras‐González, Partow Kebriaei, Elizabeth J. Shpall, David Vining, Patrick Hwu, Harpreet Singh, Carsten Reinhardt, Cedrik M. Britten, Norbert Hilf, Toni Weinschenk, Dominik Maurer, Steffen Walter   +40 more
openalex   +1 more source

Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation. [PDF]

Gene Ther
Kalland ME, Pose-Boirazian T, Palomo GM, Naumann-Winter F, Costa E, Matusevicius D, Duarte DM, Malikova E, Vitezic D, Larsson K, Magrelli A, Stoyanova-Beninska V, Mariz S.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Adoptive cell therapies in thoracic malignancies

Cancer Immunology, Immunotherapy, 2022
Immunotherapy has gained great interest in thoracic malignancies in the last decade, first in non-small cell lung cancer (NSCLC), but also more recently in small-cell lung cancer (SCLC) and malignant pleural mesothelioma (MPM). However, while 15-20% of patients will greatly benefit from immune checkpoint blockers (ICBs), a vast majority will rapidly ...
Julie Lasvergnas, Marie Naigeon, Kader Chouahnia, Laurent Zelek, Nathalie Chaput, Boris Duchemann   +5 more
openaire   +2 more sources

Adoptive T cell cancer therapy

Nature Materials, 2018
Tumour heterogeneity and off-target toxicity are current challenges of cancer immunotherapy. Karine Dzhandzhugazyan, Per Guldberg and Alexei Kirkin discuss how epigenetic induction of tumour antigens in antigen-presenting cells may form the basis for multi-target therapies.
Karine N, Dzhandzhugazyan, Per, Guldberg, Alexei F, Kirkin   +2 more
openaire   +2 more sources

Adoptive Cell Therapy

2021
Therapy in oncology has undergone a revolution in recent years. New biological agents targeting specific intra- and extracellular domains have become standard of care, immunotherapy with checkpoint inhibitors revolutionized therapy in Melanoma, Renal Cell Carcinoma, and in Non-Small Cell Lung Cancer and combinations of both are now entering clinical ...
openaire   +1 more source

Adoptive cell transfer therapy for melanoma

Experimental Dermatology, 2022
AbstractAdoptive cell transfer (ACT) of tumor‐infiltrating lymphocytes (TILs) for melanoma is an example of the most successful cancer immune therapy. It achieves a durable complete response about ~20% of patients, and they might be cured. However, the ratio of patients with durable benefits is not high, and its complicated procedure prevents its ...
openaire   +2 more sources

Adoptive cell therapies for posttransplant infections

Current Opinion in Oncology, 2019
Purpose of review Viral and fungal infections cause significant morbidity and mortality following hematopoietic stem-cell transplantation (HSCT), primarily due to the prolonged and complex immunodeficient state that results from conditioning chemo-radiotherapy and subsequent prophylaxis of graft vs. host disease.
Gaurav, Sutrave, David J, Gottlieb
openaire   +2 more sources